R&B Farma SRL
R&B Farma reported total assets of 521,346 € at the end of the 2025 financial year (annual accounts filed with the NBB on 19 Jun 2026).
The score of R&B Farma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +217 % Total assets +49 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
R&B Farma's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 92,414 € | ||||
| Equity | 298,751 € | ||||
| Cash | 156,633 € | ||||
| EBITDA | 172,632 € | ||||
| Total assets | 521,346 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 19 Jun 2026
- Year ended 31 Dec 2024filed on 30 Jul 2025
- Year ended 31 Dec 2023filed on 01 Jul 2024
- Year ended 31 Dec 2022filed on 24 Aug 2023
- Year ended 31 Dec 2021filed on 20 Jul 2022
R&B Farma's financial analysis
- Solvency57.3%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of R&B Farma
R&B Farma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0809.126.191
- VAT number
- BE0809126191
- Peppol
- Registered · 0208:0809126191 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 15 Jan 2009
- Registered office
- 2100 Antwerp
- Latest accounts
- 2025 · filed on 19 Jun 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
R&B Farma (SRL) has been based in Antwerp since 2009, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 92,414 € and equity of 298,751 €; its revenue is not published. Its solvency stands at 57.3%, above the median of its sector (44.2%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to R&B Farma
Companies in the same business, of comparable size and area, outside its group.
- Pharmacie des 4 Coins Retail sale of pharmaceutical products Namur · balance sheet 488,265 €
- Apotheek Vandenbosch C. Retail sale of pharmaceutical products Leuven · balance sheet 511,818 €
- Eifeler Apotheke Retail sale of pharmaceutical products Büllingen · balance sheet 538,478 €
- Pharmenform Retail sale of pharmaceutical products Koekelberg · balance sheet 567,837 €
- Verstraete Jeroen Apotheek Retail sale of pharmaceutical products Harelbeke · balance sheet 560,565 €
- "Farminco" Retail sale of pharmaceutical products Andenne · balance sheet 589,804 €
- Human Pharma Retail sale of pharmaceutical products Charleroi · balance sheet 434,132 €
- Vermunicht Retail sale of pharmaceutical products Hulshout · balance sheet 602,591 €
Frequently asked questions about R&B Farma
What is the revenue of R&B Farma?
R&B Farma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of R&B Farma?
In Belgium, the VAT number is the company number prefixed with BE: BE0809126191 for R&B Farma, if the company is VAT-registered. Its company number (CBE) is 0809.126.191.
Where is the registered office of R&B Farma?
According to the CBE register, the registered office of R&B Farma is in 2100 Antwerp.
What is the equity of R&B Farma?
At the close of the 2025 financial year, the equity of R&B Farma amounts to 298,751 €, a solvency of 57.3% of total assets.
Who manages R&B Farma?
The register lists 1 active mandates at R&B Farma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of R&B Farma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →